In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Featured Stories

Defining Go And No-Go Disease Areas As An R&D Business

Some believe unmet need refers only to rare diseases and tiny patient populations. But it is more than this. In 2020, the term sits at the heart of decision-making for drug makers – along with cost, access and value, of course.

Business Strategies Research and Development Strategies

Ensuring The Next Generation Of Health Care Professionals: Still An Unmet Need

For its fifth annual Future Health Index, Royal Philips chose to focus on the insights and needs of health care professionals below the age of 40, a group that often feels unheard, and yet will form the basis of the workforce over the next two decades. Getting it right from their point of view is vital.

Business Strategies Leadership Strategy

EU Health Innovation Partnership Reflects Medtech’s Role In Unmet Needs

The EU Partnership on Health Innovation, a new public private health care research partnership, is in the final drafting phase before its launch under Horizon Europe. In Vivo asked the partnership’s medtech industry lead, Patrick Boisseau, to set out the innovation challenges for participants as they address unmet health care needs in Europe.

Innovation Medical Device EU

Putting The Patient First: The Challenge And Opportunities To Improve Rare-Disease Therapy Development

Advances in identifying the genetic causes of diseases, and particularly cancers, coupled with regulatory incentives to encourage the development of therapeutic approaches to once poorly managed orphan diseases have fueled a surge in exciting new medicines. To address some of these issues and explore potential solutions, Simbec-Orion in collaboration with Informa Pharma Intelligence convened a round table of experts attending the BIO International Convention

Read More

Recent Issues

Growth Explore this Topic

Set Alert for Growth

Latest From Growth

Medtech Giants Ready To Battle Frontrunner Intuitive Surgical In 'Soft Surgery Robotics'

The global market for robotic surgery systems is expected to reach $9.7bn by 2023. With medtech giants Medtronic, Johnson & Johnson and Zimmer Biomet launching robotic platforms in 2020, this market is set for a major shakeup.

Business Strategies Commercial

Checkpoint Inhibitor Deals: Searching For IO Combinations To Unlock Cancer’s Black Box

Merck and Bristol-Myers Squibb's market-dominating checkpoint inhibitors are competing to find the next combination therapy to treat more cancer patients, in more types of cancers. Recent failures and new regulatory pressure, however, may have a cooling effect, even as researchers come full circle with PD-l/PD-L1 and CTL-4 combinations. The race is also on to pull new combinations from emerging cell therapy and precision oncology drug candidates.

Deals ImmunoOncology

Infographic: 20 Years Of Mega-Deals

The biopharma sector is often accused of a being a slow-moving engine, but a look back over the last 20 years reveals that a lot has changed. In Vivo explores the history of high-impact M&A transactions in the industry between 1999 and 2019. 

Analysis Commercial

Innovation Explore this Topic

Set Alert for Innovation

Latest From Innovation

Redbiotec Pivots Toward HSV-2 Therapies And Therapeutic Bacteria

Redbiotec has reached a new inflection point as it progresses two key programs in herpes and cancer. The company’s CEO and CSO explain how it hopes to use bacteria as a delivery system for genes or proteins to treat cancer.

Commercial Innovation

Underserved Areas: Looking Beyond Cancer And Rare Diseases

Oncology and rare diseases dominate the industry pipeline, fuelled by science, regulatory tailwinds and high prices. But as the world grapples with coronavirus, and with heart disease still the top killer, can our systems fund treatments for more prevalent conditions?

Clinical Trials Research and Development Strategies

The Tumor-Agnostic Developer’s Toolkit

In Vivo has identified the pipeline of next-generation tumor-agnostic drugs and created a guide to the ideal trial strategies for these potentially transformative candidates.

Commercial Innovation

Leadership Explore this Topic

Set Alert for Leadership

Latest From Leadership

Execs On The Move, March 2020

An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

Appointments Companies

Discussing The Past, Present And Future Of Cell And Gene Therapies

Founding CEO of the UK’s Cell and Gene Therapy Catapult, Keith Thompson, will retire from the company this year. He looks back on the last eight years of progress for CGT Catapult and the  advanced therapies sector – and provides words of wisdom for the challenges still to come.

Commercial Gene Therapy

C-Suite Snippets: Growth Of A Cell And Gene Powerhouse

In case you missed it: catch up with snippets from interviews with industry leaders recently published by In Vivo.

Business Strategies Financing

Market Access Explore this Topic

Set Alert for Market Access

Latest From Market Access

UK, Sweden Test Differing Antibiotic Market Models

Sweden and the UK are conducting differing ‘develop and test’ programs to assess so-called ‘pull’ incentives in which an antibiotics innovator will be paid an annual fee in return for an access guarantee for anti-infectives. The projects have drawn keen attention from other countries. 

Commercial Health Technology Assessment

Focusing On Collaborative Not ‘Innovative’ Ways To Pay

Innovation is defined by the Cambridge dictionary as “(the use of) a new idea or method.” The term is bandied about a great deal in the life sciences industry. Is it actually helpful to use the term so widely, or does the sector risk overlooking true innovation? This can be applied not only to the drugs coming to market, but how they are paid for as well.

Commercial Health Technology Assessment

Are Incentives Out Of Balance With Patient Need?

Incentives matter; they motivate us to do things. There is renewed interest in just what motivates the life sciences industry to make the choices it does when determining the diseases it will focus on, and how much effort it puts in. This stems from concern about too much effort going into some areas, and too little in others.

Market Access Research and Development Strategies

Market Intelligence Explore this Topic

Set Alert for Market Intelligence

Latest From Market Intelligence

Deals Shaping The Medical Industry, March 2020

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced February 2020.

Deals Financing

Fact File: Coronavirus Medtech And Diagnostic Updates

As the COVID-19 pandemic escalates, companies across the world are preparing to roll out commercial test kits for the detection of SARS-CoV-2.

Coronavirus COVID-19 Commercial

Defining Go And No-Go Disease Areas As An R&D Business

Some believe unmet need refers only to rare diseases and tiny patient populations. But it is more than this. In 2020, the term sits at the heart of decision-making for drug makers – along with cost, access and value, of course.

Business Strategies Research and Development Strategies
UsernamePublicRestriction

Register